Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system

Philip R Crain; Jamilyn M Zepp; Sara Gille; Lindsay Jenkins; Tia L Kauffman; Elizabeth Shuster; Katrina A B Goddard; Benjamin S Wilfond; Jessica Ezzell Hunter

doi:10.1186/s13053-022-00217-1

Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system

Hered Cancer Clin Pract. 2022 Apr 18;20(1):17. doi: 10.1186/s13053-022-00217-1.

Authors

Philip R Crain¹, Jamilyn M Zepp², Sara Gille³, Lindsay Jenkins³, Tia L Kauffman², Elizabeth Shuster³, Katrina A B Goddard², Benjamin S Wilfond⁴, Jessica Ezzell Hunter⁵

Affiliations

¹ Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA.
² Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
³ Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
⁴ Treuman Katz Center for Pediatric Bioethics, Department of Pediatrics, Seattle Children's Research Institute and Hospital, University of Washington School of Medicine, Seattle, WA, USA.
⁵ Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. Jessica.E.Hunter@kpchr.org.

Abstract

Introduction: Lynch syndrome (LS) is associated with an increased risk of colorectal (CRC) and endometrial (EC) cancers. Universal tumor screening (UTS) of all individuals diagnosed with CRC and EC is recommended to increase identification of LS. Kaiser Permanente Northwest (KPNW) implemented a UTS program for LS among individuals newly diagnosed with CRC in January 2016 and EC in November 2016. UTS at KPNW begins with immunohistochemistry (IHC) of tumor tissue to determine loss of mismatch repair proteins associated with LS (MLH1, MSH2, MSH6, and PMS2)., IHC showing loss of MLH1 is followed by reflex testing (automatic testing) to detect the presence of the BRAF V600E variant (in cases of CRC) and MLH1 promoter hypermethylation to rule out likely sporadic cases.

Materials and methods: Individuals newly diagnosed with CRC and EC were identified between the initiation of the respective UTS programs and July 2018. Electronic medical records were reviewed to extract patient data related to UTS, including IHC and reflex testing results, date of referrals to the genetics department, and results of germline genetic testing for LS.

Results: 313 out of 362 individuals diagnosed with CRC and 61 out of 64 individuals diagnosed with EC who were eligible were screened by IHC for LS. Most (47/52 or 90%, including 46/49 CRC and 1/3 EC) individuals that were not screened by IHC only had a biopsy sample available. Fourteen individuals (3.7% overall, including 13/313 CRC and 1/61 EC) received an abnormal result after reflex testing and were referred for genetic counseling. Of these, 10 individuals (71% overall, including 9/13 CRC and 1/1 EC) underwent germline genetic testing for LS. Five individuals diagnosed with CRC were found to have pathogenic variants. in PMS2 (n = 3), MLH1 (n = 1), and MSH6 (n = 1). No pathogenic variants were identified in individuals diagnosed with EC.

Conclusions: UTS identified individuals at risk for LS. Most individuals who screened positive for LS had follow-up germline genetic testing for LS. The consistent use of biopsy samples is an opportunity to improve UTS.

Keywords: Colorectal cancer; Genetic screening; Genetic testing; HNPCC; Lynch syndrome; Microsatellite instability.

Abstract

Grants and funding